Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

NCT00041197 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

732

Enrollment

NIH

Sponsor class

Conditions

Gastrointestinal Stromal Tumor

Interventions

DRUG: imatinib mesylate
OTHER: placebo
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)